TAM JAI INTL(02217) mid-term profit after tax was 36 million Hong Kong dollars, a decrease of 56.1% year-on-year.
Tanzi International (02217) announced that for the six months ended September 30, 2024, it achieved revenue of 1.404 billion...
TAM JAI INTL (02217) announced that, for the six months ended September 30, 2024, the company achieved revenue of 1.404 billion Hong Kong dollars, an increase of 1.23% year-on-year; the net profit after tax was 36 million Hong Kong dollars, a decrease of 56.1% year-on-year.
Related Articles
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.
SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
.png)
UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.
SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
RECOMMEND
